Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 5, 2012, Pages

  Whaley, J Taylor ^a   Levy, Lawrence B ^a   Swanson, David A ^a   Pugh, Thomas J ^a   Kudchadker, Rajat J ^a   Bruno, Teresa L ^a   Frank, Steven J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Brachytherapy; Erectile dysfunction; Penile rehabilitation; Prostate cancer; Radiation therapy; Sexual aids; Sexual function

Indexed keywords

AFTER-TREATMENT; BRACHYTHERAPY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIATION THERAPY; IODINE-125; MEDICAL DEVICES; MONO-THERAPY; PENILE BULB; POSTIMPLANT DOSIMETRY; PROSPECTIVE EVALUATION; PROSTATE BRACHYTHERAPY; PROSTATE CANCERS; QUALITY-OF-LIFE; SELF-ASSESSMENT; SEXUAL AIDS; URINARY FUNCTIONS;

DISEASES; DOSIMETRY; INDUSTRY; IODINE; ONCOLOGY; RADIOTHERAPY; UROLOGY;

OPTIMIZATION;

IODINE 125;

ADULT; AGE; AGED; ARTICLE; BRACHYTHERAPY; DIABETES MELLITUS; DOSIMETRY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; PENIS ERECTION; POTENCY DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SMOKING; URINARY TRACT FUNCTION;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COITUS; ERECTILE DYSFUNCTION; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PENILE ERECTION; PENIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 84858705593     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.11.004     Document Type: Article

References (32)

1. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008;179(5 Suppl):S20-S24. (Pubitemid 351492525)
2. Stock R, Cesaretti J, Stone N. Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 2006;64:810-816. (Pubitemid 43183579)
3. Cesaretti JA, Kao J, Stone NN, et al. Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: Analysis at ≥ 7 years of follow-up. BJU Int 2007;100:362-367. (Pubitemid 47036592)
4. van der Wielen G, Mulhall J, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: A critical review. Radiother Oncol 2007;84:107-113. (Pubitemid 47284535)
5. Merrick G, Butler W, Wallner K, et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;62:437-447. (Pubitemid 40704460)
6. Macdonald A, Keyes M, Kruk A, et al. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important? Int J Radiat Oncol Biol Phys 2005;63: 155-163. (Pubitemid 41583554)
7. Merrick GS, Wallner K, Butler W, et al. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2001;50:597-604. (Pubitemid 32519592)
8. Merrick G, ButlerW,Wallner K, et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 2002;54:1055-1062. (Pubitemid 35292616)
9. Kiteley R, Lee W, deGuzman A, et al. Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapy. Brachytherapy 2002;1:90-94. (Pubitemid 37329418)
10. Wright J, Newhouse J, Laguna J, et al. Localization of neurovascular bundles on pelvic CT and evaluation of radiation dose to structures putatively involved in erectile dysfunction after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004;59:426-435. (Pubitemid 38622597)
11. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005;32:379-395. (Pubitemid 41607527)
12. Mulhall JP, Yonover PM. Correlation of radiation dose and impotence risk after three-dimensional conformal radiotherapy for prostate cancer. Urology 2001;58:828.
13. Wallner KE, Merrick GS, Benson ML, et al. Penile bulb imaging. Int J Radiat Oncol Biol Phys 2002;53:928-933. (Pubitemid 34722638)
14. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899-905.
15. SandaMG, Miller D,Wei JT. Utilization of Sexual Medications/Devices. http://www.rtog.org/LinkClick.aspx?fileticket=AbvkbNgSN-k%3D&tabid=290
16. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-1261. (Pubitemid 351439226)
17. Pinkawa M, Asadpour B, Piroth MD, et al. Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancerda matched-pair comparison. Radiother Oncol 2009;91:225-231.
18. Stock RG, Cesaretti JA, Stone NN. Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 2006;64:810-816. (Pubitemid 43183579)
19. Gillan C, Kirilova A, Landon A, et al. Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography. Int J Radiat Oncol Biol Phys 2006;65:688-693. (Pubitemid 43795815)
20. Merrick GS, Wallner K, Butler WM, et al. Short-term sexual function after prostate brachytherapy. Int J Cancer 2001;96:313-319. (Pubitemid 32946477)
21. Selek U, Cheung R, Lii M, et al. Erectile dysfunction and radiation dose to penile base structures: A lack of correlation. Int J Radiat Oncol Biol Phys 2004;59:1039-1046. (Pubitemid 38834296)
22. Frank SJ, Fisher C, Levy LB, et al. Pre-implant urinary symptoms predict for worse urinary outcomes (abstract 2745). Int J Radiat Oncol Biol Phys 2008;72(1 Suppl):S502.
23. Lehrer S, Cesaretti J, Stone NN, et al. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. BJU Int 2006;98:979-981. (Pubitemid 44536443)
24. Ash D, Bottomley D, Al-Qaisieh B, et al. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother Oncol 2007;84:135-139. (Pubitemid 47284527)
25. Takashima R, Egawa S, Kuwao S, et al. Anterior distribution of stage T1c nonpalpable tumors in radical prostatectomy specimens. Urology 2002;59:692-697. (Pubitemid 34461979)
26. Byar DR, Mostofi FK. Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies examined by the step-section technique. Cancer 1972;30:5-13.
27. Frimmel H, Egevad L, Bengtsson E, et al. Modeling prostate cancer distributions. Urology 1999;54:1028.
28. Merrick GS, Wallner KE, Butler WM. Minimizing prostate brachytherapy-related morbidity. Urology 2003;62:786-792. (Pubitemid 37421218)
29. McLaughlin P, Narayana V, Pan C, et al. Comparison of day 0 and day 14 dosimetry for permanent prostate implants using stranded seeds. Int J Radiat Oncol Biol Phys 2006;64:144-150. (Pubitemid 41831221)
30. Acher P, Rhode K, Morris S, et al. Comparison of combined x-ray radiography and magnetic resonance (XMR) imaging-versus computed tomography-based dosimetry for the evaluation of permanent prostate brachytherapy implants. Int J Radiat Oncol Biol Phys 2008;71: 1518-1525.
31. Tanaka O, Hayashi S, Matsuo M, et al. MRI-based preplanning in low-dose-rate prostate brachytherapy. Radiother Oncol 2008;88: 115-120. (Pubitemid 351888891)
32. DiBiase SJ, Hosseinzadeh K, Gullapalli R, et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002;52:429-438. (Pubitemid 34170847)